Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
US ambassador to India Richard R. Verma on Friday said India is worst effected by tuberculosis (TB) and needs more efforts to fight the disease. Verma said TB was grabbing and finishing India. He said every year 2.2 million people were becoming victim of TB.
In a world's first, a group of cardiologists has successfully used the eye-wearable device Google Glass to guide the opening up of a chronically blocked right coronary artery in the cardiac cath lab.
A drug currently used in the treatment of Type II diabetes can also be effective in clearing fatty liver disease from some patients, a significant research has found.
Two £10 million manufacturing research Hubs that will address major, long-term challenges facing the UK’s manufacturing industries, and capture opportunities from emerging research were announced today by Universities and Science Minister Jo Johnson.
[adsense:336x280:8701650588]
(BWI); Portea Medical, India’s largest home healthcare company, today announced that it has acquired specialty pharmaceutical distributor MedybizPharma in a move that will enable Portea to strengthen patient engagement and provide better care for chronic disease patients in India.
With over 12,500 dengue cases in Delhi, a green NGO claimed that the ongoing fogging drive in the city was "not effective" in fighting thevector-borne disease, and has rather "harmful" effects on health, as the gas contains "95 per cent" of diesel in it. Saying that fogging only creates a "false" sense of security and is a way of "appeasing" people at the cost of their health, Centre for Science and Environment (CSE) urged the government to focus on systematic preventive measures towards clean environment and sanitation.
TESARO, Inc., an oncology-focused biopharmaceutical company, announced that VARUBI™ (rolapitant), an NK-1 receptor antagonist, is now available in the United States. The U.S. Food and Drug Administration (FDA) approved VARUBI on Sept. 1, 2015, for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
The European Commission (EC) has granted orphan drug designation to Retrophin Inc's sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).
Meridian Bioscience, Inc. announced it has received clearance from the U.S. Food and Drug Administration (FDA) for new claims for its illumigene® Pertussis molecular amplification test. The upgraded test reduces the effect of inhibitors in biologic samples and significantly expands Meridian’s customer base by including specimens collected by ESwab™ (Copan Diagnostics, Inc.).
ESwab is a multipurpose universal transport system that a significant portion of laboratories in the United States currently use to streamline workflows and eliminate costs associated with stocking multiple swab types.
BioSyent Inc. ("BioSyent") announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of CYSVIEW®, a new photosensitizer for the detection and management of papillary Non-Muscle Invasive Bladder Cancer (NMIBC).
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
